Anatomical location of the primary tumour and its relationship to regional lymph node metastasis in cutaneous head and neck melanoma: Is selective neck dissection appropriate?

2020 ◽  
Vol 73 (4) ◽  
pp. 783-808
Author(s):  
Joshua J Dale ◽  
Sukhbir Rayatt ◽  
Nick White ◽  
Demetrius Evriviades ◽  
James Baden
Cancer ◽  
2017 ◽  
Vol 124 (3) ◽  
pp. 514-520 ◽  
Author(s):  
Moran Amit ◽  
Samantha Tam ◽  
Ahmed S. Abdelmeguid ◽  
Dianna B. Roberts ◽  
Shaan M. Raza ◽  
...  

2015 ◽  
Vol 8 ◽  
pp. CMENT.S19874 ◽  
Author(s):  
Ismail Zohdi ◽  
Louay S. El Sharkawy ◽  
Mahmoud F. El Bestar ◽  
Hazem M. Abdel Tawab ◽  
Mo'men A.A. Hamela ◽  
...  

Objectives To evaluate the effectiveness of selective neck dissection of sublevel IIa and level III in cases of glottis and supraglottic laryngeal carcinoma in the absence of lymph node metastasis and to show if there is value in dissecting the sublevel IIb or level IV in these cases. Patients and Methods Twenty-five patients with N0 glottic or supraglottic cancer were subjected to unilateral or bilateral selective neck dissection according to the site and the extent of the tumor, and the specimens were histopathologically examined for metastasis. Results Twenty-five patients (23 males and 2 females) with mean age of 55.72 years were included in the study. Lymph node metastasis to sublevel IIa and level III was found in 6/25 (24%) cases with glottic or supraglottic carcinoma, while to sublevel IIb and level IV was found in 1/25 (4%) with P-value of 0.05, which is statistically significant. Conclusion Selective neck dissection of level IIb is not required in cases of the supraglottic laryngeal cancer. Dissection of sublevel IIa and level III takes less time and is effective. Dissection of level IV is not needed in the case of supraglottic cancer.


2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 68-68
Author(s):  
Onal Cem ◽  
Nese Torun ◽  
Ozan Cem Guler ◽  
Mehmet Reyhan ◽  
Berna Akkus Yildrim ◽  
...  

68 Background: The aim was to assess the intensity of 68Ga-PSMA uptake in the primary tumour in patients locally advanced prostate cancer treated with definitive radiotherapy. Also correlation between the maximum standardized uptake value (SUVmax) of primary tumour and the Gleason score (GS) or prostate-specific antigen (PSA) level was assessed. Methods: The data of 201 biopsy-proven prostated cancer patients were retrospectively analysed. Median age of entire cohort was 68 years (range; 45 – 85 years). PET/CT images were analysed visually and semiquantitatively by measuring the SUVmax. The SUVmax of the primary tumour was assessed in relation to both PSA level and GS. Results: Median age of entire cohort was 68 years (ranged 45 – 85 years). Median PSA value at diagnosis was 20.3 ng/mL (ranged 2.1 – 301.0 ng/mL). Forty-two patients (23.9%) was in intermediate risk group, and 159 patients (79.1%) had high risk disease. Seventy two patients (36.8%) had regional lymph node metastasis. Median SUVmax of primary tumor and metastatic lymph nodes were 13.0 (ranged 1.3 - 84.3) and 12.6 (ranged 3.6 – 64.5), respectively. Patients with GS 7 or lower had significantly lower SUVmax compared to patients with GS > 7 (12.1±8.4 vs. 20.9±16.4; p < 0.001). However, there was no significant difference in SUVmax of tumors with GS of 3+4 and 4+3 (14.8±8.6 vs. 16.3±12.7; p = 0.6). Patients with PSA ≥10.0 ng/mL exhibited significantly higher uptake than those with PSA levels < 10.0 ng/mL (12.1±8.4 vs. 20.9±16.4; p < 0.001). SUVmax of intermediate risk patients was significantly lower than that of high risk patients (12.7±11.1 vs. 19.8±16.8; p = 0.01). In 72 patients with lymph node metastasis SUVmax was significantly higher compared to 129 patients without lymph node metastasis (24.9±21.3 vs. 14.7±10.6; p < 0.001). Conclusions: Tumours with GS 7 or lower, patients with PSAvalues ≤10 ng/mL, intermediate risk patients and patients without regional lymph node metastasis showed significantly lower 68Ga-PSMA uptake. 68Ga-PSMA-PET/CT should be preferentially applied for primary staging of prostate cancer in patients with GS > 7, PSA levels ≥10 ng/ml, high risk patients and patients with regional lymph node metastasis.


2000 ◽  
Vol 110 (7) ◽  
pp. 1210-1214 ◽  
Author(s):  
Ludwig E. Smeele ◽  
Charles R. Leemans ◽  
Colin B.A. Reid ◽  
Rammohan Tiwari ◽  
Gordon B. Snow

Author(s):  
O.E. Abramova ◽  
◽  
D.V. Kudryavtsev ◽  
Yu.V. Gumenetskaya ◽  
◽  
...  

Basal cell carcinoma (BCC) is the most common cancer of the skin, it accounts for 75-97% of all skin tumors. Nowadays, there is a wide range of local treatment options for BCC. The disease frequently occurs in the head and neck region. Because BCC tends to recur, it is necessary to find the most effective treatment option for the disease with account of cosmetic results. Although the BCC prevalence is rather high, metastatic disease occurs rarely (0,008-0,55%). Maybe it is the reason for lack of recurrent BCC patients management algorithm in the current clinical guide-lines. The article presents the report of clinical observations on the development, treatment and outcomes of recurrent BCC in the occipital region with cervical lymph node metastasis. Neck lymph nodes were treated with two-phase conventionally fractionated radiotherapy to the total dose of 60 Gy. For treatment of recurrent BCC in the occipital region we performed a course of external beam radiation therapy to the total dose of 66 Gy followed by the 6 month targeted ther-apy with the SMO inhibitor vismodegib (a smoothened transmembrane protein). There was no evidence of disease recurrence 11 months after the therapy completion. Radiotherapy in combi-nation with targeted therapy was shown to be highly effective and safe treatment of recurrent, lo-cally advanced BCC in the head and neck with regional lymph node metastases. The used method seems to be a reasonable alternative approach to the treatment of BCC when other con-servative therapy options have been exhausted and surgical therapy is not possible.


2018 ◽  
Vol 142 (12) ◽  
pp. 2518-2528 ◽  
Author(s):  
Maxime Mermod ◽  
Agnès Hiou-Feige ◽  
Esther Bovay ◽  
Vincent Roh ◽  
Jana Sponarova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document